Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$3.2M
Program Spending
90%
of total expenses go to program services
Total Contributions
$1.4M
Total Expenses
▼$5M
Total Assets
$4.3M
Total Liabilities
▼$775.2K
Net Assets
$3.5M
Officer Compensation
→$670.1K
Other Salaries
$2.4M
Investment Income
$180.6K
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$284.7K
Awards Found
1
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| National Science Foundation | STTR PHASE I: NEW PARADIGM FOR COMBINATION DRUG OPTIMIZATION AND DISCOVERY -THE BROADER IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (STTR) PHASE I PROJECT IS IN ADDRESSING DIRECTLY THE CHALLENGE OF OPTIMIZING THE USE AND DISCOVERY OF DRUG COMBINATIONS. EFFECTIVE COMBINATION DRUG THERAPIES OPTIMIZE THE THERAPEUTIC EFFECTS OF THESE DRUGS AND MINIMIZE HARMFUL AND/OR UNCOMFORTABLE SIDE EFFECTS. MANY DISEASES, INCLUDING CANCER, ALZHEIMER?S, HEART DISEASE, AND LIFE-THREATENING INFECTIONS, ARE TREATED BY DRUGS USED IN COMBINATION. AMAZINGLY, THE USE OF THESE DRUG COMBINATION IS GUIDED BY ANALYTICAL METHODS THAT ARE OVER 100 YEARS OLD. RESEARCHERS HAVE DEVELOPED THE FIRST COMPONENTS OF A NEW ANALYTICAL TOOLKIT FOR COMBINATION DRUG DISCOVERY AND DEVELOPMENT ACROSS A RANGE OF DISEASE INDICATIONS. THIS STTR PHASE 1 RESEARCH PROJECT WILL ENABLE THE COMMERCIALIZATION OF THIS TOOLKIT BY DISCOVERING HOW TO HARNESS THE POWER OF ARTIFICIAL INTELLIGENCE (AI) TO SIFT THROUGH A RANGE OF EXISTING (AND FUTURE) LABORATORY AND CLINICAL DATA TO FIND THE DRUG COMBINATIONS THAT WORK BEST. THE COMBINATION DRUG TOOLKIT MAY CREATE SIGNIFICANT VALUE FOR ITS CUSTOMERS BY (1) IMPROVING TARGET SELECTION, (2) REDUCING THE NUMBER OF DRUG DEVELOPMENT PROGRAMS THAT FAIL, (3) INCREASING THE EFFICIENCY OF CLINICAL TRIALS DATA ANALYSIS, AND (4) EXTENDING THE PATENT LIFE OF IMPORTANT DRUGS WITH NEW VIABLE COMBINATIONS. THE PROPOSED PROJECT SEEKS TO LEVERAGE IMPROVEMENTS IN QUANTITATIVE UNDERSTANDING OF DRUG ? DRUG SYNERGY TO OVERCOME CHALLENGES ASSOCIATED WITH THE OPTIMIZATION AND DISCOVERY OF COMBINATION DRUG THERAPIES. THE MULTIDIMENSIONAL SYNERGIES OF COMBINATION (MUSYC) ALGORITHM IS VALUED AS AN IMPROVEMENT IN UNDERSTANDING DRUG ? DRUG SYNERGY BY RIGOROUSLY DEFINING SYNERGY OF EFFICACY AND SYNERGY OF POTENCY AND EXTRACTING THESE DIFFERENT SYNERGIES FROM EXPERIMENTAL DATA SETS. THE PROPOSED RESEARCH SEEKS TO INNOVATE THE MEANS OF DATA PRODUCTION AND INTEGRATION ACROSS DIVERSE DATA SOURCES AND MERGE THIS WITH ADDITIONAL RELEVANT DATABASES AND CLINICAL DATA TO CREATE AN EFFECTIVE ANALYTICAL TOOLKIT FOR OPTIMIZING ALL STAGES OF COMBINATION DRUG RESEARCH AND DEVELOPMENT. THE RESEARCH PLAN CONSISTS OF AN EXPERIMENTAL TRACK AND A COMPUTATIONAL TRACK. THE EXPERIMENTAL TRACK WILL USE THE MUSYC ALGORITHM TO INFORM EXPERIMENTAL DESIGN AND HIGH-THROUGHPUT DATA COLLECTION FOR THREE USE CASES OF CONSIDERABLE CLINICAL RELEVANCE. IN PARALLEL, THE ARTIFICIAL INTELLIGENCE/MACHINE LEARNING APPROACHES WILL BE USED TO INTEGRATE DIVERSE DATA SETS WITH THE MUSYC ALGORITHM TO PREDICT SYNERGIES OF COMBINATIONS. THE DATA TRACK AND THE AI-TRACK WILL THEN BE MERGED TO PROVIDE PROOF-OF-CONCEPT FOR AN AI-ENABLED MUSYC TOOLKIT FOR OPTIMIZING COMBINATION DRUG USE AND DISCOVERY. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD. | $284.7K | FY2025 | Mar 2025 – Feb 2026 |
National Science Foundation
$284.7K
STTR PHASE I: NEW PARADIGM FOR COMBINATION DRUG OPTIMIZATION AND DISCOVERY -THE BROADER IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (STTR) PHASE I PROJECT IS IN ADDRESSING DIRECTLY THE CHALLENGE OF OPTIMIZING THE USE AND DISCOVERY OF DRUG COMBINATIONS. EFFECTIVE COMBINATION DRUG THERAPIES OPTIMIZE THE THERAPEUTIC EFFECTS OF THESE DRUGS AND MINIMIZE HARMFUL AND/OR UNCOMFORTABLE SIDE EFFECTS. MANY DISEASES, INCLUDING CANCER, ALZHEIMER?S, HEART DISEASE, AND LIFE-THREATENING INFECTIONS, ARE TREATED BY DRUGS USED IN COMBINATION. AMAZINGLY, THE USE OF THESE DRUG COMBINATION IS GUIDED BY ANALYTICAL METHODS THAT ARE OVER 100 YEARS OLD. RESEARCHERS HAVE DEVELOPED THE FIRST COMPONENTS OF A NEW ANALYTICAL TOOLKIT FOR COMBINATION DRUG DISCOVERY AND DEVELOPMENT ACROSS A RANGE OF DISEASE INDICATIONS. THIS STTR PHASE 1 RESEARCH PROJECT WILL ENABLE THE COMMERCIALIZATION OF THIS TOOLKIT BY DISCOVERING HOW TO HARNESS THE POWER OF ARTIFICIAL INTELLIGENCE (AI) TO SIFT THROUGH A RANGE OF EXISTING (AND FUTURE) LABORATORY AND CLINICAL DATA TO FIND THE DRUG COMBINATIONS THAT WORK BEST. THE COMBINATION DRUG TOOLKIT MAY CREATE SIGNIFICANT VALUE FOR ITS CUSTOMERS BY (1) IMPROVING TARGET SELECTION, (2) REDUCING THE NUMBER OF DRUG DEVELOPMENT PROGRAMS THAT FAIL, (3) INCREASING THE EFFICIENCY OF CLINICAL TRIALS DATA ANALYSIS, AND (4) EXTENDING THE PATENT LIFE OF IMPORTANT DRUGS WITH NEW VIABLE COMBINATIONS. THE PROPOSED PROJECT SEEKS TO LEVERAGE IMPROVEMENTS IN QUANTITATIVE UNDERSTANDING OF DRUG ? DRUG SYNERGY TO OVERCOME CHALLENGES ASSOCIATED WITH THE OPTIMIZATION AND DISCOVERY OF COMBINATION DRUG THERAPIES. THE MULTIDIMENSIONAL SYNERGIES OF COMBINATION (MUSYC) ALGORITHM IS VALUED AS AN IMPROVEMENT IN UNDERSTANDING DRUG ? DRUG SYNERGY BY RIGOROUSLY DEFINING SYNERGY OF EFFICACY AND SYNERGY OF POTENCY AND EXTRACTING THESE DIFFERENT SYNERGIES FROM EXPERIMENTAL DATA SETS. THE PROPOSED RESEARCH SEEKS TO INNOVATE THE MEANS OF DATA PRODUCTION AND INTEGRATION ACROSS DIVERSE DATA SOURCES AND MERGE THIS WITH ADDITIONAL RELEVANT DATABASES AND CLINICAL DATA TO CREATE AN EFFECTIVE ANALYTICAL TOOLKIT FOR OPTIMIZING ALL STAGES OF COMBINATION DRUG RESEARCH AND DEVELOPMENT. THE RESEARCH PLAN CONSISTS OF AN EXPERIMENTAL TRACK AND A COMPUTATIONAL TRACK. THE EXPERIMENTAL TRACK WILL USE THE MUSYC ALGORITHM TO INFORM EXPERIMENTAL DESIGN AND HIGH-THROUGHPUT DATA COLLECTION FOR THREE USE CASES OF CONSIDERABLE CLINICAL RELEVANCE. IN PARALLEL, THE ARTIFICIAL INTELLIGENCE/MACHINE LEARNING APPROACHES WILL BE USED TO INTEGRATE DIVERSE DATA SETS WITH THE MUSYC ALGORITHM TO PREDICT SYNERGIES OF COMBINATIONS. THE DATA TRACK AND THE AI-TRACK WILL THEN BE MERGED TO PROVIDE PROOF-OF-CONCEPT FOR AN AI-ENABLED MUSYC TOOLKIT FOR OPTIMIZING COMBINATION DRUG USE AND DISCOVERY. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD.
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $3.2M | $1.4M | $5M | $4.3M | $3.5M |
| 2022 | $4.9M | $3.7M | $4.3M | $7.3M | $7.1M |
| 2021 | $2.6M | $1.3M | $4M | $6.8M | $6.5M |
| 2020 | $3.3M | $2.1M | $4.2M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Michael Larsson | President & | 40 | $162K | $0 | $19.5K | $181.5K |
| Michele Carroll | Secr/treas/c | 40 | $155.8K | $0 | $7,836 | $163.6K |
Michael Larsson
President &
$181.5K
Hrs/Wk
40
Compensation
$162K
Related Orgs
$0
Other
$19.5K
Michele Carroll
Secr/treas/c
$163.6K
Hrs/Wk
40
Compensation
$155.8K
Related Orgs
$0
Other
$7,836
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Jahfree Duncan | Sr Dir Degre | 40 | $143.4K | $0 | $6,908 | $150.3K |
| Elizabeth Pimentel | Chief Ext Re | 40 | $136.3K | $0 | $13.9K | $150.3K |
| Mary Leviner | Sr Dir Stude | 40 | $118.4K | $0 | $17K | $135.4K |
| Khaleel Shreet | Sr Coach & M | 40 | $108K | $0 | $591 | $108.6K |
Jahfree Duncan
Sr Dir Degre
$150.3K
Hrs/Wk
40
Compensation
$143.4K
Related Orgs
$0
Other
$6,908
Elizabeth Pimentel
Chief Ext Re
$150.3K
Hrs/Wk
40
Compensation
$136.3K
Related Orgs
$0
Other
$13.9K
Mary Leviner
Sr Dir Stude
$135.4K
Hrs/Wk
40
Compensation
$118.4K
Related Orgs
$0
Other
$17K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Julie Swerdlow Albino | Director | 1 | $0 | $0 | $0 | $0 |
| Stig Leschly | Chair | 2 | $0 | $0 | $0 | $0 |
| Thabiti Brown | Director | 1 | $0 | $0 | $0 | $0 |
Julie Swerdlow Albino
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Stig Leschly
Chair
$0
Hrs/Wk
2
Compensation
$0
Related Orgs
$0
Other
$0
Thabiti Brown
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
| $8.1M |
| $7.9M |
| 2019 | $5.2M | $4.5M | $3.1M | $8.6M | $8.5M |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
Khaleel Shreet
Sr Coach & M
$108.6K
Hrs/Wk
40
Compensation
$108K
Related Orgs
$0
Other
$591